Prescription drug · NDA
Doptelet Sprinkle (avatrombopag) NDC 71369-010
Avatrombopag maleate 10 mg/1 · Granule · Oral · AkaRx, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71369-010-30 | 71369001030 | 1 BOTTLE in 1 CARTON (71369-010-30) / 30 GRANULE in 1 BOTTLEMarketed from Jul 25, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Doptelet Sprinkle
- Generic name (nonproprietary)
- avatrombopag
- Active ingredients
- Avatrombopag maleate — 10 mg/1
- Dosage form
- Granule
- Route
- Oral
- Labeler
- AkaRx, Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 219696
- Marketing start
- Listing expires
- Identifiers
- Product ID 71369-010_4d4d84be-34cd-4027-b69a-2f16ec5049edSPL ID 4d4d84be-34cd-4027-b69a-2f16ec5049edSPL set ID e2d5960d-6c18-46cc-86bd-089222b09852RxCUI 2045951, 2045952, 2045958, 2045959, 2045960, 2045961, 2721188, 2721192UNII GDW7M2P1IS
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471369001030followed by a unit qualifier and the quantityPackage 71369-0010-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1.1 ) Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. ( 1.2 ) Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment ( 1.3 ) 1.1 Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD) DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who ar…
Excerpt only. Read the full label for complete information.